Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 12: 1977

INSERM U 463, Hôtel-Dieu, Nantes, France.
Leukemia (Impact Factor: 10.43). 01/1999; 12(12):1977-82. DOI: 10.1038/sj.leu.2401211
Source: PubMed


In this study, we show that malignant plasma cells from patients with either primary (n=12) or secondary (n=15) plasma cell leukemia (PCL) do not express CD56 at all, neither in the bone marrow nor the peripheral blood in 81% of cases. On the other hand, multiple myeloma (MM) at diagnosis overexpress it in 63 of 94 (67%) cases (P=0.0001). In three secondary PCL evaluated serially, CD56 was also lacking at diagnosis showing that CD56 is not downregulated at the end stage of the disease but rather not upregulated in this subset of patients. This last concept is strengthened by the observation that 29% of MM patients lacking CD56 or weakly expressing it at diagnosis present a detectable leukemic phase vs 11% only in CD561 MM (P=0.06). Forty percent of all the CD56(-/weak) malignant plasma cell disorders present or develop a leukemic phase vs only 15% of CD56+ cases (P < 0.008). CD56(-/weak) MM subset is also associated with a significantly less aggressive osteolytic potential (P=0.012). We conclude that the lack or weak expression of CD56 is a characteristic feature of PCL but also delineates a special subset of MM at diagnosis mainly characterized by a lower osteolytic potential and a trend for malignant plasma cells to circulate in the peripheral blood more overtly.

Download full-text


Available from: Catherine Pellat-Deceunynck, Jul 15, 2014
1 Follower
91 Reads
  • Source
    • "In plasma cells, aberrant expression of CD56 and CD28 but lack of CD19 and CD27 showed the association with malignancy [3]. Downregulation of CD56 and a higher expression of CD44 have been associated with extramedullary spreading of malignant plasma cells [4, 5] and expression of CD28 has been related to disease activity [6, 7]. Though many studies have reported the associations between the expression of several antigens, including CD19, CD28, CD56, and CD117, and patient prognosis [8–10], no consensus has been reached regarding the expression status of antigens and their clinical relevance. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated the association between the expression of myeloid antigens on neoplastic plasma cells and patient prognosis. The expression status of CD13, CD19, CD20, CD33, CD38, CD56, and CD117 was analyzed on myeloma cells from 55 newly diagnosed patients, including 36 men (65%), of median age 61 years (range: 38-78). Analyzed clinical characteristics and laboratory parameters were as follows: serum β 2-microglobulin, lactate dehydrogenase, calcium, albumin, hemoglobin, serum creatinine concentrations, bone marrow histology, and cytogenetic findings. CD13+ and CD33+ were detected in 53% and 18%, respectively. Serum calcium (P = 0.049) and LDH (P = 0.018) concentrations were significantly higher and morphologic subtype of immature or plasmablastic was more frequent in CD33+ than in CD33- patients (P = 0.022). CD33 and CD13 expression demonstrate a potential prognostic impact and were associated with lower overall survival (OS; P = 0.001 and P = 0.025) in Kaplan-Meier analysis. Multivariate analysis showed that CD33 was independently prognostic of shorter progression free survival (PFS; P = 0.037) and OS (P = 0.001) with correction of clinical prognostic factors. This study showed that CD13 and CD33 expression associated with poor prognosis in patients with MM implicating the need of analysis of these markers in MM diagnosis.
    BioMed Research International 06/2014; 2014:893243. DOI:10.1155/2014/893243 · 2.71 Impact Factor
  • Source
    • " się obecność plazmocytów we krwi obwodowej w ilości > 2×10 9 /L lub więcej niż 20% krwinek białych. W porównaniu do IgG(+) lub IgA(+) PCMs białaczka plazmocytowa zdarza się częściej w przypadku produkcji łańcucha lekkiego, IgD lub IgE, przez nowotworowe komórki plazmatyczne. Ponadto cechą różniącą PCL od pozostałych PCNs jest brak ekspresji CD56 [Pellat-Deceunynck i wsp. 1998, Rawstron i wsp. 1999]. PCL znacznie pogarsza rokowanie w PCNs. Ocena ilości krążących PCs u świeżo rozpoznanych pacjentów z PCMs za pomocą FCM potwierdza znaczenie obecności krążących komórek nowotworowych jako niezależnego od innych uznanych parametrów laboratoryjnych czynnika prognostycznego dla czasu całkowitego przeżycia (OS) [Nowa"
    [Show abstract] [Hide abstract]
    ABSTRACT: This chapter reviews themost relevant diagnostic techniques (histopathology, cytology and immunophenotyping) currently used for the evaluation of patients with plasma cell neoplasms (PCNs). Although the bone marrow morphological examination of the PCNs still remains the „gold standard” technique for the fast, accurate and cost-effective diagnostics, other assays such as immunophenotyping estimated by immunohistochemistry and flow cytometry, DNA cell content and cell cycle analysis measured by flow cytometry, cytogenetics studies and fluorescence in situ hybridization of neoplastic cells may contribute to a better assessment ofmyeloma patients. Here, we discuss not only the contribution of each of these techniques to differential diagnosis of monoclonal gammopathies, but also the value of each of biological parameters as prognostic factors. We postulate that all abovementioned techniques, besides standard morphological methods, should be used for the routine diagnostics of PCNs cases.
    SZPICZAK MNOGI KOMPLEKSOWA DIAGNOSTYKA I TERAPIA, Edited by JURCZYSZYN A, SKOTNICKI A.B, 01/2010: chapter Histopathological, cytological and immunophenotypical characteristics of the plasma cell neoplasms: pages 17-30; W GÓRNICKI.
Show more